Outcomes in patients with clinical Stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site

Urology

Volumn 79, Issue 5, 2012, Pages 1079-1084

  Masterson, Timothy A ^a,b   Carver, Brett S ^a,b   Shayegan, Bobby ^a,b   Feldman, Darren R ^a,b   Motzer, Robert J ^a,b   Bosl, George J ^a,b   Sheinfeld, Joel ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RELAPSE; CANCER STAGING; DIAGNOSTIC IMAGING; DISEASE SPECIFIC SURVIVAL; FEMALE; FIBROSIS; FOLLOW UP; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NONSEMINOMATOUS GERM CELL TUMOR; PARAAORTIC LYMPH NODE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM, RESIDUAL; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; RETROPERITONEAL SPACE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860485513     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.11.090     Document Type: Article

References (27)

1. G.J. Bosl, R. Gluckman, N.L. Geller VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors J Clin Oncol 4 1986 1493 1499 (Pubitemid 17183573)
2. L.H. Einhorn Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal foundation award lecture Cancer Res 41 1981 3275 3280 (Pubitemid 11063588)
3. International Germ Cell Cancer Collaborative Group International Germ Cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers J Clin Oncol 15 1997 594 603
4. B.S. Carver, A.M. Serio, D. Bajorin Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors J Clin Oncol 25 2007 5603 5608
5. A.J. Stephenson, J. Sheinfeld The role of retroperitoneal lymph node dissection in the management of testicular cancer Urol Oncol 22 2004 225 235
6. G.E. Carter, G. Lieskovsky, D.G. Skinner Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors J Urol 138 1987 1397 1401 (Pubitemid 18006811)
7. J.P. Donohue, R.G. Rowland, K. Kopecky Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer J Urol 137 1987 1176 1179 (Pubitemid 17079050)
8. W.A. Gelderman, H. Schraffordt Koops, D.T. Sleijfer Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy J Surg Oncol 38 1988 227 232
9. P.C. Stomper, M.S. Jochelson, M.B. Garnick Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology AJR Am J Roentgenol 145 1985 743 746 (Pubitemid 16216507)
10. Karellas M, Carver BS, Stasi J, et al. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection for men with CII non-seminomatous germ cell tumors and a radiographically normal retroperitoneum. [Abstract 830] AUA Annual Meeting 2007.
11. G.C. Toner, D.M. Panicek, R.T. Heelan Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection J Clin Oncol 8 1990 1683 1694 (Pubitemid 20334323)
12. P.C. Brenner, H.W. Herr, M.J. Morse Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis J Clin Oncol 14 1996 1765 1769 (Pubitemid 26185453)
13. M.E. Gels, H.J. Hoekstra, D.T. Sleijfer Thoracotomy for postchemotherapy resection of pulmonary residual tumor mass in patients with nonseminomatous testicular germ cell tumors: aggressive surgical resection is justified Chest 112 1997 967 973 (Pubitemid 27446316)
14. J.T. Hartmann, M. Candelaria, M.A. Kuczyk Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours Eur J Cancer 33 1997 843 847 (Pubitemid 27287033)
15. I. Mandelbaum, P.B. Yaw, L.H. Einhorn The importance of one-stage median sternotomy and retroperitoneal node dissection in disseminated testicular cancer Ann Thorac Surg 36 1983 524 528 (Pubitemid 13022815)
16. M.S. McGuire, F. Rabbani, H. Mohseni The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours BJU Int 91 2003 469 473 (Pubitemid 36570562)
17. H.L. Qvist, S.D. Fossa, S. Ous Post-chemotherapy tumor residuals in patients with advanced nonseminomatous testicular cancer Is it necessary to resect all residual masses? J Urol 145 1991 300 303
18. P. Tiffany, M.J. Morse, G. Bosl Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors Cancer 57 1986 978 983 (Pubitemid 16166151)
19. P.G. Tognini, R.S. Foster, P. McGraw Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology J Urol 159 1998 1833 1835 (Pubitemid 29190707)
20. B. Shayegan, B.S. Carver, R.J. Motzer Impact of residual extra-retroperitoneal masses in patients with advanced non-seminomatous germ cell testicular cancer J Urol 175 2006 449A
21. L. Cheng, S. Zhang, M. Wang Molecular genetic evidence supporting the neoplastic nature of stromal cells in "fibrosis" after chemotherapy for testicular germ cell tumours J Pathol 213 2007 65 71 (Pubitemid 47354567)
22. E.W. Steyerberg, H.J. Keizer, J.E. Messemer ReHiT Study Group Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor: prediction of histology Cancer 79 1997 345 355 (Pubitemid 27029899)
23. N.E. Jacobsen, S.D. Beck, L.E. Jacobson Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? J Urol 184 2010 949 953
24. M. Karellas, B.S. Carver, J. Stasi Clinical outcome following PC-RPLND for men with clinical stage II NSGCT and a radiographically normal retroperitoneum J Urol 177 2007 277
25. J. Oldenburg, G.C. Alfsen, H.H. Lien Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses J Clin Oncol 21 2003 3310 3317 (Pubitemid 46606265)
26. Y. Ehrlich, M.J. Brames, S.D. Beck Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28 2010 531 536
27. T.A. Masterson, B. Shayegan, B.S. Carver et al. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer Urology 79 2012 156 159